title: Long-term treatment of lupus nephritis with cyclosporin A.
abstract: We evaluated the efficacy and safety of long-term treatment with cyclosporin A (CSA) in type IV lupus nephritis. Seventeen patients with biopsy-proven WHO type IV lupus nephritis were enrolled in a prospective, open study. Twelve of the 17 completed 48 months of treatment with CSA and prednisolone. Three patients required the addition of azathioprine, at 12, 38 and 47 months, respectively, for cutaneous disease flare with refractory rashes. One patient was lost to follow-up at 40 months. The mean +/- SD duration of treatment was 43.2 +/- 10.1 months (range 15.7-48 months). A significant reduction of proteinuria and a significant rise in serum albumin were noted 1 month after initiation of treatment. Improvement was maintained throughout the study except for three patients who relapsed with recurrence of nephrotic syndrome. There were no significant changes in serum creatinine level or creatinine clearances throughout the study. Repeat renal biopsy at 12 months following treatment with CSA showed histological improvement, with WHO type II changes in all 17 patients accompanying significant reduction in activity indices. Patients with baseline haemoglobin (Hgb) levels < 12 g/dl showed significant improvement. Serum C3 and C4 levels were not changed significantly. Corticosteroid-sparing effects were noted. Side-effects included hypertension, gum hypertrophy and mild hirsuitism, but were not serious. Combination therapy using CSA and prednisone is effective and safe for long-term treatment in lupus patients with WHO type IV nephritis.
authors.affiliation: Department of Medicine and Clinical Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong.
authors.forename: L S
authors.initials: LS
authors.lastname: Tam
authors.forename: E K
authors.initials: EK
authors.lastname: Li
authors.forename: C B
authors.initials: CB
authors.lastname: Leung
authors.forename: K C
authors.initials: KC
authors.lastname: Wong
authors.forename: F M
authors.initials: FM
authors.lastname: Lai
authors.forename: A
authors.initials: A
authors.lastname: Wang
authors.forename: C C
authors.initials: CC
authors.lastname: Szeto
authors.forename: S F
authors.initials: SF
authors.lastname: Lui
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011446:Prospective Studies; D011507:Proteinuria / Q000188:drug therapy; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D006454:Hemoglobins; D007166:Immunosuppressive Agents; D012709:Serum Albumin; D016572:Cyclosporine; D011239:Prednisolone